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Tumour necrosis factor-(TNF)-neutralizing strategies represent a major breakthrough in the treatment of rheumatoid arthritis (RA) [1] , ankylosing spondylitis (AS) and psoriatic arthritis (PsA) [2] . However, there is a large heterogeneity in the response to these agents. Therapy with TNF-blockers is expensive and bears substantial risks. Predictors of treatment response would, therefore, be useful to select the appropriate patients for treatment. Recently, a French study showed that RA patients with the À308 TNF promoter G/G genotype have a better response to TNF-blockade with infliximab than those with the À308A allele [3] . In another study, patients with the rare allele of the promoter polymorphism 196 of the p75 TNF receptor showed a poorer response to anti-TNF therapy [4] . In addition, a recent Swedish study demonstrated that the combination of the diplotypes À308 G/G in the TNF promoter and of À1087G/G in the interleukin (IL-10) gene was associated with good responsiveness to etanercept [5] . In the present study, we demonstrate a prognostic impact of the À308 TNF promoter polymorphism regarding not only the responsiveness of RA patients to infliximab but also to etanercept and adalimumab. In addition, we present data for similar observations in spondyloarthritis patients.
Patients and methods
A total of 54 patients with RA, 10 patients with PsA and 22 patients with AS diagnosed according to the American College of Rheumatology [6] and modified New York criteria [7] required treatment with infliximab (Essex, Luzern CH), adalimumab (Abbott, Baar, CH) or etanercept (Wyeth, Zug, CH). The patients received infusions of infliximab or subcutaneous injections of adalimumab or etanercept according to standard protocols. Fifty-three RA, 10 PsA patients and 11 AS patients continued with s.c. weekly low-dose methotrexate (MTX). One RA patient received leflunomide (20 mg/day), and three AS patients were comedicated with azathioprine (50-150 mg/day). Three AS patients started with MTX after the onset of TNF-blockade. Approval of the study was obtained from the Local Ethical Committee (Canton of Berne), and informed consent was obtained from all patients.
Response was assessed after 24 weeks of treatment. For RA and PsA patients, the modified disease activity score (DAS28) was used [8] [9] [10] . Disease activity of AS patients was assessed using the Bath Ankylosing Spondylitis Activity Index (BASDAI) [11] . We used a detailed categorization of response: in RA and PsA moderate response corresponded to a DAS28 improvement of !1.2 and 2.2, and good response to an improvement of >2.2 from baseline. Consequently, treatment failure was defined as an improvement in DAS28 <1.2.
In the group of AS patients, a moderate response was defined as an improvement in BASDAI of !20 and 50%, and a BASDAI improvement of >50% from baseline corresponded to a good response [11] . Non-responders were defined as having a BASDAI improvement of <20%.
Genomic DNA was extracted from whole blood using a commercially available kit (Qiagen, Hilden, Germany). Genotypes were determined with the use of fluorogenic allele-specific oligonucleotide probes (TaqMan assay I). Primer pairs were designed to match the À308G or À308A allele, resulting in amplification of the target sequence. Genotype calling was carried out with the allelic discrimination analysis module of the ABI PRISM Õ 7700 SDS (software version 1.7). Patients, characteristics and quantitative measures are presented as mean AE S.D. compared with Students, two-tailed t-test. A P-value <0.05 was regarded as statistically significant. Association analyses of treatment response with À308 TNF promoter diplotypes (A/A, A/G, G/G), the allelic status (À308A absent or present), or the anti-TNF agents used in this study were done by 2 test. All statistics were done with the software package SPSS Õ version 12.0 (SPSS Munich, Germany).
Results
In Table 1 , basis demographics, disease status and drug treatment of RA and AS patients were compared according with their À308 genotype (A/A, A/G, G/G). RA patients with the A/A and A/G genotypes tended to be younger than those with the G/G genotype. There were no significant differences in prednisolone and DMARD comedication at study entry. About 61.1% of RA patients received infliximab, 22.2% etanercept and 16.7% were treated with adalimumab. Mean disease duration of AS patients was somehow longer in those with the A/G genotype compared with their G/G-positive counterparts (16.8 vs 9.5 yr; P < 0.025). The vast majority of AS patients was treated with infliximab (94.1%), and only one patient with adalimumab. Table 2 demonstrates the division of RA, PsA and AS patients according to the À308 genotype that resulted in groups of comparable disease activity at baseline as indicated by the mean DAS28 or the mean BASDAI but of significantly different improvement of DAS28 and BASDAI scores with anti-TNF treatment. The clinical outcome of anti-TNF treatment in RA patients was closely associated with the À308 TNF promoter diplotype (n ¼ 54, 2 ¼ 96.72, P < 0.001) and to the presence or absence of an A allele at locus À308 ( 2 ¼ 43,43, P < 0.001). Good response was exclusively observed in patients carrying the À308 G/G diplotype, whereas moderate response was associated with the À308 A/G genotype in 14/14, and unresposiveness with the À308 AA diplotype in 3/3 patients.
In agreement with the results in RA patients, response to anti-TNF treatment was associated with the allelic status (n ¼ 32, 2 ¼ 26.75, P < 0.001) and genotype ( 2 ¼ 26.75, P < 0.001) at position À308 in the entire cohort of SpA patients (pooled data of AS and PsA patients) and in AS patients when analysed in separate (n ¼ 20, 2 ¼ 22.00, P < 0.001). Strong prediction of treatment response was suggested by association analyses for the allelic status (n ¼ 86, 2 ¼ 70.17, P < 0.001) and genotype ( 2 ¼ 115.50, P < 0.001) of the entire study cohort.
All good responders were identified in the group of G/G-positive patients irrespective of their disease, whereas moderate responders mostly carried the A/G genotype (90%) and much less the G/G genotype (6.3%). In contrast, nonresponders belonged either to the A/A (three RA patients) or to the A/G group (two AS patients). Robustness of these results was further supported by separate analyses for both genders (female: n ¼ 45, 2 ¼ 72.38, P < 0.001; male: n ¼ 42, 2 ¼ 42.00, P < 0.001) or by analyses only of female RA patients (n ¼ 37, 2 ¼ 26.56, P < 0.001) or of male SpA patients (n ¼ 24, 2 ¼ 24.00, P < 0.001). However, association analyses of the treatment response to infliximab, adalimumab or etanercept were not significantly different (n ¼ 86, 2 ¼ 4.93).
Discussion
In the present study, 54 patients with RA, 10 with PsA and 22 with AS who were treated with TNF-blocking agents, either with infliximab, adalimumab or with etanercept, were followed up. We examined whether the clinical response at 24 weeks could be predicted by the TNF promoter genotype at position À308. Our analysis supports previous findings [3] on the importance of the À308 TNF promoter polymorphism for the response to infliximab of RA patients. In addition, our results provide evidence for similar associations in other inflammatory conditions good responses) , carriers of the G/G genotype by far outweighed patients with the A/G genotype in the group of good responders. In contrast, A/G carriers had a 14-fold higher probability of achieving only a moderate response compared with patients with the G/G genotype. The rare A/A genotype was strongly associated with non-response in our RA patients. In fact, we calculated a 10-fold higher probability of non-response in this group of patients compared with patients with the A/G genotype. This is the first study reporting the importance of a TNF polymorphism predicting response to TNF-blocking agents not only in RA but also in PsA and AS. A previous study in Crohn's disease did not find any influence of À308 TNF gene polymorphism on the response to infliximab [12] , and a Swedish group found that only a combination of the G/G genotype of the À308 TNF promoter and the À1087 G/G genotype of IL-10 was associated with good responsiveness to etanercept in RA patients [5] . Our patients were comparable with regard to age and disease duration, but in contrast to the Swedish study, our RA patients were all on parenteral MTX, which is known to have a higher bioavailability compared with oral MTX [13] . One can argue that the more intensive MTX comedication had an impact on baseline inflammtory cytokine levels before starting with TNF-blockers, rendering patients more sensitive to TNF neutralization. This hypothesis is supported by our own studies on the effect of MTX on the IL-1 pathway [14] . It suggests a synergistic role of the two therapeutic strategies regarding the proinflammatory cytokine network. Another explanation is the inhibitory effect of MTX on the production of neutralizing antibodies to the TNF-blocking molecules. Furthermore, it has previously been reported that MTX reduces the clearance of TNF-blocking antibodies and thereby increases the bioactivity and the clinical response [15] . These mechanisms could also explain the substantially higher response rate of our RA patients with A/G or G/G genotypes compared with a French cohort of patients [3] .
Our data furthermore support the previous observation [16] that a rapid CRP reduction upon TNF-blockade was associated with the clinical response in RA patients (data not shown).
The results of clinical studies [16, 17] showing that some patients not responding to one TNF-blocker may respond to the treatment with another TNF-blocking agent, however, are not supported and cannot be explained by our data. Whether it is the locus investigated here, the presence of distinct TNF haplotypes or MHC genes linked to -308 A/G as discussed elsewhere remains to be elucidated [3, 18, 19] . Similar results in RA and SpA, diseases of completely different genetic background, give rise to the assumption that the TNF gene, rather than the class I or class II MHC genes, is of importance for the response to TNFblockade.
Collectively, the presented results illustrate that the TNF promoter is important determinant of treatment response irrespective of genetic associations of the underlying diseases. Significance levels for RA and AS were determined by Student's two-tailed t-test comparing different groups of genotypes: A/G vs A/A, G/G vs A/A and G/G vs A/G; *PsA, significance level of (intra G/G genotype group) improvement; data are presented as mean AE S.D. NS, not significant.
